Few molecules have generated as many publications in such a short time as retatrutide. Since the first phase 2 trial results, it has become a central reference for any lab researching the GLP-1/GIP/glucagon metabolic pathways.
A novel molecular architecture
Where earlier generations of metabolic research molecules targeted only one receptor (GLP-1), then two (GLP-1/GIP), retatrutide is the first studied molecule to simultaneously activate three receptors: GLP-1, GIP, and glucagon.
Two concentrations for research
NOVALYXLABS offers retatrutide in 10 mg and 20 mg, as well as a complete starter pack with reconstitution accessories. Every batch is tested via UPLC/MS with a Certificate of Analysis.
Note: retatrutide, like all NOVALYXLABS products, is strictly intended for scientific research in laboratory settings, not for human or animal consumption. No information in this article constitutes medical advice.